The forum opened with remarks from Dr. George M. Ragheb Maher, CEO of MARC, and Dr. Khaled Abu Zaid, CEO of Expert Consult, who emphasized the importance of regional collaboration and a shared patient-centered mission. Technical sessions featured leading experts discussing model-informed drug development, virtual bioequivalence, regulatory decision-making, mechanistic safe-space evaluation, ICH M15 developments, and population pharmacokinetics in bioequivalence study design. The event concluded with an open panel discussion on the opportunities, challenges, and roadmap for adopting MIDD and virtual bioequivalence across the region. With participation from experts and regulatory representatives across several Arab countries, the forum highlighted growing momentum toward faster, safer, and more efficient drug development focused on improving patient outcomes.